» Articles » PMID: 20876310

HIF-1α Regulates Function and Differentiation of Myeloid-derived Suppressor Cells in the Tumor Microenvironment

Abstract

Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8(+) T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate-oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.

Citing Articles

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.


Association of immunosuppressive CD45CD33CD14 CD10HLA-DR neutrophils with poor prognosis in patients with lymphoma and their expansion and activation through STAT3/arginase-1 pathway .

Xiao M, Zhou J, Zhang W, Ding Y, Guo J, Liang X Cytojournal. 2025; 21:69.

PMID: 39916996 PMC: 11801647. DOI: 10.25259/Cytojournal_165_2024.


The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.

Wang Q, Yu M, Zhang S Front Immunol. 2025; 15:1440830.

PMID: 39877377 PMC: 11772360. DOI: 10.3389/fimmu.2024.1440830.


Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome It.

Mendoza E, Ciriolo M, Ciccarone F Antioxidants (Basel). 2025; 14(1).

PMID: 39857427 PMC: 11762716. DOI: 10.3390/antiox14010094.


Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.

Arleo A, Montagner A, Giovannini C, Suzzi F, Piscaglia F, Gramantieri L Biomolecules. 2025; 14(12.

PMID: 39766202 PMC: 11673139. DOI: 10.3390/biom14121496.


References
1.
Monu N, Frey A . Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer Res. 2007; 67(23):11447-54. PMC: 3712860. DOI: 10.1158/0008-5472.CAN-07-1441. View

2.
Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee J . Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007; 13(16):4840-8. DOI: 10.1158/1078-0432.CCR-07-0409. View

3.
Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

4.
Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

5.
Talmadge J . Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007; 13(18 Pt 1):5243-8. DOI: 10.1158/1078-0432.CCR-07-0182. View